BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21263190)

  • 1. Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
    Rohrberg KS; Skov BG; Lassen U; Christensen IJ; Høyer-Hansen G; Buysschaert I; Pappot H
    Cancer Biomark; 2010; 7(3):141-51. PubMed ID: 21263190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray.
    Kim HS; Park YH; Lee J; Ahn JS; Kim J; Shim YM; Kim JH; Park K; Han J; Ahn MJ
    Cancer; 2010 Feb; 116(3):676-85. PubMed ID: 20052735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor.
    Fei J; Hong A; Dobbins TA; Jones D; Lee CS; Loo C; Al-Ghamdi M; Harnett GB; Clark J; O'Brien CJ; Rose B
    Ann Surg Oncol; 2009 Oct; 16(10):2908-17. PubMed ID: 19603236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular determinants in targeted therapy for esophageal adenocarcinoma.
    Vallböhmer D; Peters JH; Kuramochi H; Oh D; Yang D; Shimizu D; DeMeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; Danenberg PV; DeMeester TR
    Arch Surg; 2006 May; 141(5):476-81; discussion 481-2. PubMed ID: 16702519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
    Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
    J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
    Lieto E; Ferraraccio F; Orditura M; Castellano P; Mura AL; Pinto M; Zamboli A; De Vita F; Galizia G
    Ann Surg Oncol; 2008 Jan; 15(1):69-79. PubMed ID: 17896140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis.
    Loges S; Clausen H; Reichelt U; Bubenheim M; Erbersdobler A; Schurr P; Yekebas E; Schuch G; Izbicki J; Pantel K; Bokemeyer C; Fiedler W
    Clin Cancer Res; 2007 Jan; 13(1):76-80. PubMed ID: 17200341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.
    de Jong JS; van Diest PJ; van der Valk P; Baak JP
    J Pathol; 1998 Jan; 184(1):53-7. PubMed ID: 9582527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?
    Millikan KW; Mall JW; Myers JA; Hollinger EF; Doolas A; Saclarides TJ
    Am Surg; 2000 Apr; 66(4):401-5; discussion 405-6. PubMed ID: 10776879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis.
    Khorana AA; Ryan CK; Cox C; Eberly S; Sahasrabudhe DM
    Cancer; 2003 Feb; 97(4):960-8. PubMed ID: 12569594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.